Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05652374

Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study

The GT RACING is a study comparing the efficacy of HA-CS bladder installations with prophylactic antibiotics in the prevention of recurrent urinary tract infections (rUTI).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Radboudumc, Nijmegen, Gelderland, Netherlands

Loading trial locations.

About this study

The main objective of the study is to compare efficacy between hyaluronic acid - chondroitin sulphate (HA-CS) treatment and gold standard treatment (AB prophylaxis). Study is set-up as non-inferiority, parallel group cross-over RCT, with a 1:1 randomization.

Study population: Female (>18rs) with at least 3 symptomatic urinary tract infections (UTI's) in the previous year with no adequate curable therapeutic options.

Intervention: 50ml of sterile Ialuril (HA 1.6% CS 2%) weekly for 6 weeks, followed by monthly maintenance therapy for 6 months.

Control : oral nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily will be given.

All patients recieve both treatments (ialuril and nitrofurantoin) consecutively, for 6 months each. The order of the therapies is determined by randomisation. Between therapies there is a 4 weeks 'wash-out' period. A total of 100 patients will be included.

During the study patients will fill-out questionnaires regarding symptoms, quality of life and use of healthcare. Furthermore urine will be collected at set timepoints.

Main study parameters/endpoints: The main study parameter is the number of UTI per patient-year. Secondary parameters are time to rUTI (wks.), outcome on the global responce assessment (GRA) scale, pattern of antibiotic resistance, outcome on the patient reported outcome questionnaire, cost effectiveness and Quality-of-life.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult female patients (>18 years) who had at least 3 symptomatic UTI's in the previous year with no adequate curable therapeutic options (e.g. bladder stones)
  • At least one UTI's must be confirmed with a positive culture and antibiogram, further UTI's must be confirmed with a urine sediment with positive nitrite or a positive culture.

Exclusion criteria

  • Male
  • < 18 years
  • Pregnant
  • Already on GAG therapy
  • Already on prophylactic antibiotics
  • Started or stopped cranberry/d-mannose therapy or vaginal estrogenic creme in the last two months
  • Had Gentamicin or other antibiotic instillations in the previous 2 months
  • Allergic to >3 regular used antibiotics in Dutch guidelines (ed. Nitrofurantoin, trimethoprim, Fosfomycin)
  • A urinary fistula
  • Urinary stones
  • Urogenital cancer
  • Bladder Pain Syndrome - Interstitial Cystitis
  • Chronic pelvic pain
  • Had a STD untreated or treated in the previous 2 months
  • A urinary diversion
  • An Indwelling catheter
  • A suprapubic catheter
  • Performing >1/day self-catheterization
  • A residue after voiding (PVR) of >200ml
  • Unable (also legal) to give informed consent
  • Recurrent urosepsis
  • Multiresistant bacteria in previous urine cultures
  • Contra-indications and interactions for Nitrofurantoin: severe kidney disfunction (GFR < 30), lung- or liver problems or neuropathy after previous use of nitrofurantoin, acute porphyria, known G6PD deficiency, use of magnesium trisilicate.
  • Contra-indications and interactions for trimethoprim: severe kidney or liver dysfunction, blood count abnormality, use of vitamin K antagonists, use of folic acid antagonists, use of ace inhibitors
  • Severe lung/respiratory disfunction (reduced lung capacity, lung cancer, fibrosis, COPD)
  • Does not tolerate catheterization

Treatment and study plan

Ialuril 50ml Prefill

Device

50ml of sterile Ialuril (HA 1.6% CS 2%) bladder instillations weekly for 6 weeks, followed by monthly maintenance therapy for 6 months

Other names: HA-CS

Nitrofurantoin

Drug

nitrofurantoin 100mg daily (1dd100mg or 2dd50mg) for 6 months. ( In case of resistance/intolerance/allergy for nitrofurantoin alternatively trimethoprim 100mg daily)

Primary outcomes

  1. Number of urinary tract infections

    Time frame: 13 months

    Number of urinary tract infections per patient-year

Secondary outcomes

  1. Time to first urinary tract infection

    Time frame: 13 months

    Time to first urinary tract infection

  2. Global Assessment of Improvement

    Time frame: 7 weeks, 3 months, 6 months after start of each therapy

    Changes on Global Assessment of Improvement, Likert scale: -3 (worst) to +3(best)

  3. Antibiotics resistance

    Time frame: Baseline, 6 months after start of each therapy

    Difference in acquired AB resistance (increase in resistance to different antibiotic treatments) between both patients groups

  4. Cost-effectiveness: medical consumption questionnaire

    Time frame: Baseline, 6 months after start of each therapy

    Difference in cost-effectiveness between the 2 therapies. This is assessed with the 'medical consumption questionnaire'

  5. Cost-effectiveness: productivity cost questionnaire

    Time frame: Baseline, 6 months after start of each therapy

    Difference in cost-effectiveness between the 2 therapies. This is assessed with the 'productivity cost questionnaire'

  6. Therapy specific patient reported outcomes (symptoms & bother)

    Time frame: baseline, 7 weeks, 3 months, 6 months after start of each therapy

    Differences in therapy specific patient reported outcomes between both patient groups (measured in Therapy Specific Patient Reported Outcome (PRO) Questionnaire on Symptom & Bother rUTI & GAG therapy)

  7. General quality of life questionnaire (mobility, self-care, daily activities, pain/discomfort, anxiety/depression)

    Time frame: baseline, 7 weeks, 3 months, 6 months after start of each therapy

    Is there a difference in the Quality-of-life between the 2 therapies during follow-up using ED-5D 5L questionnaire

Study contacts

Contact information is provided by the study sponsor or research team.

Cléo Baars, MD

CONTACT

[email protected]

+31 6 15400527

Dick Janssen, MD, PhD

CONTACT

[email protected]

+31 6 41856516

Sponsors and collaborators

Lead sponsor

Radboud University Medical Center

Other

Collaborators

  • Goodlife Pharma B.V.
  • IBSA Institut Biochimique SA

Registry information

Acronym: GT RACING

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Dec 15, 2022
Registry last updated
Nov 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.